Adults with B-cell precursor acute lymphoblastic leukemia (ALL) who achieve CR may still relapse1,2

Going deeper by measuring minimal residual disease (MRD)

MRD is an important prognostic indicator that may be useful for predicting relapse3

In adult B-cell ALL,

Over a 10 year period, patients who achieved MRD negativity had a greater chance of survival vs patients who remained MRD+3,*

Clinical guidelines recommend testing for MRD5

2017 NCCN Clinical Pratice Guidelines in Oncology (NCCN Guidelines®) for ALL recommends MRD assessment upon completion of initial induction therapy and states:

“MRD is an essential component of patient evaluation over the course of sequential therapy”

Get more facts and keep MRD testing a priority in your practice:


*According to a meta-analysis of 5 studies evaluating 806 adult patients with ALL.

CR, complete response; CR2, second complete response.

References: 1. Hoelzer D. Am Soc Clin Oncol Educ Book. 2013;33:290‐293. 2. Jain N, et al. In: Hoffman R, et al, eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA: Saunders-Elsevier; 2013:960-980. 3. Berry DA, et al. JAMA Oncol. 2017;3:e170580. 4. Gökbuget N, et al. Blood. 2012;120:1868-1876. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.5.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed January 9, 2018. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.